Europe Head And Neck Cancer Therapeutics Market Size, Share & Industry Trends Analysis Report By Therapy Type (Immunotherapy, Chemotherapy, and Targeted Therapy), By Route of Administration, By Distribution Channel, By Country and Growth Forecast, 2022 - 2028

The Europe Head And Neck Cancer Therapeutics Market should witness market growth of 11.6% CAGR during the forecast period (2022-2028).

The risk of dissemination to other areas of the body via the bloodstream is directly connected to whether cancer has progressed to the lymph nodes in the neck, the number of lymph nodes involved, and the location of the lymph nodes in the neck. The risk is greater if cancer is present in lymph nodes in the lower neck, as opposed to merely those in the upper neck.

The detection of cancer of the head and neck is frequently established by a dentist, oral surgeon, or physician when a patient detects signs such as a lump in the neck or a nonhealing sore in the mouth. During a normal examination, the diagnosis can be determined even in the absence of symptoms.

Head and neck cancer encompass epithelial malignancies of the upper aerodigestive tract (UADT), which includes the paranasal sinuses, oral cavity, nasal cavitypharynx, and larynx; and as the sixth most prevalent cancer worldwide, head and neck cancer accounts for approximately 6% of solid tumors. Annually, around 650,000 new cases of head and neck cancer are detected, resulting in approximately 350,000 deaths.

The incidence of neck dissection is a quality measure for the treatment of oral cavity cancer at Germany's approved head and neck cancer clinics. Neck dissections will be performed on 76% of oral cavity cancer cases treated in accredited facilities. Healthcare expenditures in the United Kingdom have climbed by 4% annually. In 1960, it represented less than 5% of the gross domestic product (GDP); fifty years later, it represents over 10% of the GDP. Current projections indicate that within ten years, unmanaged healthcare spending will outpace economic growth and become unsustainable.

The Germany market dominated the Europe Head & Neck Cancer Therapeutics Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $165 Million by 2028. The UK market is anticipated to grow at a CAGR of 10.7% during (2022-2028). Additionally, The France market would exhibit a CAGR of 12.4% during (2022-2028).

Based on Therapy Type, the market is segmented into Immunotherapy, Chemotherapy, and Targeted Therapy. Based on Route of Administration, the market is segmented into Injectable and Oral. Based on Distribution Channel, the market is segmented into Retail & Specialty Pharmacies, Hospital Pharmacies, and Online Pharmacies. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.

The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include Eli Lilly and Company, Merck & Co., Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Teva Pharmaceuticals Industries Ltd., F. Hoffmann-La Roche Ltd., AstraZeneca Plc, Bristol Myers Squibb Company, and Clinigen Group PLC.

Scope of the Study

By Therapy Type

• Immunotherapy
• Chemotherapy
• Targeted Therapy

By Route of Administration

• Injectable
• Oral

By Distribution Channel

• Retail & Specialty Pharmacies
• Hospital Pharmacies
• Online Pharmacies

By Country

• Germany
• UK
• France
• Russia
• Spain
• Italy
• Rest of Europe

Key Market Players

List of Companies Profiled in the Report:

• Eli Lilly and Company
• Merck & Co., Inc.
• Sanofi S.A.
• Takeda Pharmaceutical Company Limited
• Teva Pharmaceuticals Industries Ltd.
• F. Hoffmann-La Roche Ltd.
• AstraZeneca Plc
• Bristol Myers Squibb Company
• Clinigen Group PLC

Unique Offerings

• Exhaustive coverage
• The highest number of market tables and figures
• Subscription-based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free